Metisazone
Names | |
---|---|
IUPAC name [(1-Methyl-2-oxoindol-3-ylidene)amino]thiourea | |
Other names Metisazone | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
ECHA InfoCard | 100.016.016 |
EC Number |
|
KEGG |
|
MeSH | D008720 |
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C10H10N4OS |
Molar mass | 234.28 g/mol |
Pharmacology | |
J05AA01 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references |
Methisazone (USAN) or metisazone (INN)[1] is an antiviral drug that works by inhibiting mRNA and protein synthesis, especially in pox viruses. During trials in the 1960s it showed promising results against smallpox infection, but widespread use was considered logistically impractical in the developing countries facing smallpox cases, and it saw only limited use. In developed countries able to cope with the logistic challenge, treatment of smallpox could be achieved just as effectively with immunoglobulin therapy, without the severe nausea associated with metisazone.[2]
Methisazone has been described as being used in prophylaxis since at least 1965.[3][4]
The condensation of N-methylisatin with thiosemicarbazide leads to methisazone.[citation needed]
References
- ^ Aromatic thiosemicarbazones, their antiviral action and interferon. 1. The decreasing of adenovirus type 1 resistance against interferon by methisazone in vitro, Yuriy V. Patskovsky*, Emma N. Negrebetskaya, Alexandra A. Chernomaz, Tamara P. Voloshchuk, Eugeniy L. Rubashevsky, Oleg E. Kitam, Mikhail I. Tereshchenko, Lidiya N. Nosach, Anatoliy I. Potopalsky
- ^ Fenner, Frank; Henderson, Donald A; Arita, Isa; Jezek, Zdenek; Ladnyi, Ivan Danilovich (1988). Smallpox and its eradication. Geneva: World Health Organization. p. 67. hdl:10665/39485. ISBN 9241561106.
- ^ do Valle, LA; de Melo, PR; de Gomes, LF; Proença, LM (13 Nov 1965). "Methisazone in prevention of variola minor among contacts". Lancet. 2 (7420): 976–8. doi:10.1016/s0140-6736(65)92840-0. PMID 4159212.
- ^ Weiss MM, Weiss PD, Mathisen G, Guze P (December 2004). "Rethinking smallpox". Clin. Infect. Dis. 39 (11): 1668–73. doi:10.1086/425745. PMC 7107961. PMID 15578369.
- v
- t
- e
Herpesvirus |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HPV/MC | |||||||||||||
Vaccinia | |||||||||||||
Poxviridae |
Nucleic acid inhibitors | |
---|---|
Interferon | |
Multiple/unknown |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e